SHERBOC: A Double-blind, Placebo-controlled, Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Hormone Receptor-positive, Heregulin Positive (HRG+), HER2 Negative Metastatic Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 24 Nov 2017
At a glance
- Drugs Seribantumab (Primary) ; Fulvestrant
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms SHERBOC
- Sponsors Merrimack Pharmaceuticals
- 08 Nov 2017 According to a Merrimack Pharmaceuticals media release, Top-line results are expected in the first half of 2018.
- 30 Oct 2017 According to a Merrimack Pharmaceuticals media release, the first patient is expected to be dosed in the study by the end of 2017.
- 10 Oct 2017 Status changed from not yet recruiting to recruiting.